Compound Summary
Compound Information
cisplatin
Compound Name: | cisplatin |
Compound CID: | 5702198 |
Synonyms: | cisplatin 14913-33-8 Transplatin trans-Dichlorodiamineplatinum(II) azane;dichloroplatinum More... |
Iupac Name: | azane;dichloroplatinum |
InChI: | InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2 |
InChIKey: | LXZZYRPGZAFOLE-UHFFFAOYSA-L |
Canonical Smiles: | N.N.Cl[Pt]Cl |
Isomeric Smiles: | N.N.Cl[Pt]Cl |
Molecular Weight: | 300.05 |
Molecular Formula: | Cl2H6N2Pt |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
cisplatin
Molecular Weight: | 300.05 |
Molecular Formula: | Cl2H6N2Pt |
Hydrogen Bond Donor Count: | 2 |
Hydrogen Bond Acceptor Count: | 2 |
Rotatable Bond Count: | 0 |
Heavy Atom Count: | 5 |
Complexity: | 2.8 |
Synonyms
cisplatin
| cisplatin | cisplatin |
|---|---|
cisplatin |
14913-33-8 |
Transplatin |
trans-Dichlorodiamineplatinum(II) |
azane;dichloroplatinum |
H6Cl2N2Pt |
trans-Diamminedichloro platinum(II) |
trans-Platinum(II)diammine dichloride |
MFCD00011623 |
CACP |
trans-Dichlorodiamineplatinum(II);Transplatin |
Platinum, diamminedichloro-, (SP-4-1)- |
SR-05000001586 |
IA call |
Cisplatin in water |
Cisplatin,(S) |
Cisplatin in DMSO |
DDP-H |
PLATINOL (TN) |
Cl.2H3N.Pt |
SPECTRUM1502107 |
Cisplatin (JP17/USP/INN) |
cis-Dichlorodiamine platinum(II) |
HMS502M12 |
Trans-Platinum diammine dichloride |
HMS1921J18 |
HMS2092D04 |
BCP01792 |
BCP18182 |
7433AA |
CCG-39901 |
AKOS005137969 |
NSC-119875 |
NCGC00094962-01 |
NCGC00094962-02 |
NCGC00094962-03 |
H878 |
FT-0777996 |
C06911 |
D00275 |
J90019 |
cis-Diammineplatinum(II) dichloride, crystalline |
913C338 |
Q412415 |
SR-01000076254 |
trans-Diamminedichloroplatinum(II), Pt 64.5% min |
SR-01000076254-1 |
SR-05000001586-1 |
SR-05000001586-3 |
Cisplatin, European Pharmacopoeia (EP) Reference Standard |
Cisplatin, United States Pharmacopeia (USP) Reference Standard |
cis-Diamineplatinum(II) dichloride, >=99.9% trace metals basis |
Cisplatin impurity A, European Pharmacopoeia (EP) Reference Standard |
Transplatin, United States Pharmacopeia (USP) Reference Standard |
Cisplatin, Pharmaceutical Secondary Standard; Certified Reference Material |
Experimental Data
cisplatin
| Species | Dosage | Unit | CG Lifespan(AVG/MED days) | TG Lifespan(AVG/MED days) | Lifespan Change(AVG/MED%) | CG Lifespan(MAX days) | TG Lifespan(MAX days) | Lifespan Change(MAX%) | Significant | Strain | Gender | PubMed | Active Label |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 0.01 | mM | 11.27 | 9.3 | -0.17 | S | N2 | 34142816 | Inactive | ||||
| Caenorhabditis elegans | 0.02 | mM | 11.27 | 8.66 | -0.23 | S | N2 | 34142816 | Inactive | ||||
| Caenorhabditis elegans | 0.05 | mM | 11.27 | 7.18 | -0.36 | S | N2 | 34142816 | Inactive | ||||
| Caenorhabditis elegans | 33 | umol/L | -5 | NS | N2 | 24134630 | Inactive |
Experimental Data Visualization
cisplatin
Statistics Data
cisplatin
| Species | Lifespan Change(AVG/MED%) | Lifespan Change(MAX%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | -0.17 | 2 | 4 |
Statistics Data Visualization
cisplatin
